General Information of Drug (ID: DMRX748)

Drug Name
PMID27019002-Compound-20a Drug Info
Cross-matching ID
TTD Drug ID
DMRX748

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IMG-7289 DML9AVG Acute myeloid leukaemia 2A60 Phase 2 [2]
CC-90011 DM0EDHJ Lymphoma 2A80-2A86 Phase 2 [2]
CC-90011 DM0EDHJ Lymphoma 2A80-2A86 Phase 2 [3]
Vafidemstat DM64ZGY Alzheimer disease 8A20 Phase 2 [4]
ORY-2001 DMYM0UY Alzheimer disease 8A20 Phase 2 [5]
INCB59872 DMRLV7G Acute myeloid leukaemia 2A60 Phase 1/2 [2]
GSK2879552 DMT3V2W Small-cell lung cancer 2C25.Y Phase 1 [6]
Seclidemstat DMCP7SD Ewing sarcoma 2B52 Phase 1 [7]
TAS-1440 DMHIA7Y Acute myeloid leukaemia 2A60 Phase 1 [8]
Tarnylcypromine derivative 2 DMEJR2F N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase (MAO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [9]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [9]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [9]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [9]
Methylene blue DMJAPE7 Acquired methemoglobinemia 3A93 Approved [10]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [9]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [9]
Ergoloid mesylate DMORPBA Alzheimer disease 8A20 Approved [11]
Cyclopropylamine derivative 11 DMMJ0YN N. A. N. A. Patented [1]
Cyclopropylamine derivative 9 DMX7YAL N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysine-specific histone demethylase 1 (LSD) TTNR0UQ KDM1A_HUMAN Inhibitor [1]
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [1]

References

1 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
4 Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
5 Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
6 A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
7 Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
8 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
9 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
10 Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.